BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18794106)

  • 1. Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN.
    Woodward ER; Ricketts C; Killick P; Gad S; Morris MR; Kavalier F; Hodgson SV; Giraud S; Bressac-de Paillerets B; Chapman C; Escudier B; Latif F; Richard S; Maher ER
    Clin Cancer Res; 2008 Sep; 14(18):5925-30. PubMed ID: 18794106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.
    Maher ER
    World J Urol; 2018 Dec; 36(12):1891-1898. PubMed ID: 29680948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
    Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
    J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?
    Johannesma PC; Houweling AC; Menko FH; van de Beek I; Reinhard R; Gille JJ; van Waesberghe JT; Thunnissen E; Starink TM; Postmus PE; van Moorselaar RJ
    Fam Cancer; 2016 Apr; 15(2):297-300. PubMed ID: 26603437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion.
    Schneider M; Dinkelborg K; Xiao X; Chan-Smutko G; Hruska K; Huang D; Sagar P; Harisinghani M; Iliopoulos O
    Fam Cancer; 2018 Jan; 17(1):135-139. PubMed ID: 28623476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial non-syndromic clear cell renal cell carcinoma.
    Woodward ER
    Curr Mol Med; 2004 Dec; 4(8):843-8. PubMed ID: 15579031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
    Petersson F; Gatalica Z; Grossmann P; Perez Montiel MD; Alvarado Cabrero I; Bulimbasic S; Swatek A; Straka L; Tichy T; Hora M; Kuroda N; Legendre B; Michal M; Hes O
    Virchows Arch; 2010 Apr; 456(4):355-65. PubMed ID: 20300772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report of Birt-Hogg-Dubé Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer.
    Dong L; Gao M; Hao WJ; Zheng XQ; Li YG; Li XL; Yu Y
    Medicine (Baltimore); 2016 May; 95(22):e3695. PubMed ID: 27258496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescent and chromogenic in situ hybridization of CEN17q as a potent useful diagnostic marker for Birt-Hogg-Dubé syndrome-associated chromophobe renal cell carcinomas.
    Kato I; Iribe Y; Nagashima Y; Kuroda N; Tanaka R; Nakatani Y; Hasumi H; Yao M; Furuya M
    Hum Pathol; 2016 Jun; 52():74-82. PubMed ID: 26980015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer.
    Bartram MP; Mishra T; Reintjes N; Fabretti F; Gharbi H; Adam AC; Göbel H; Franke M; Schermer B; Haneder S; Benzing T; Beck BB; Müller RU
    BMC Med Genet; 2017 May; 18(1):53. PubMed ID: 28499369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer.
    Nahorski MS; Lim DH; Martin L; Gille JJ; McKay K; Rehal PK; Ploeger HM; van Steensel M; Tomlinson IP; Latif F; Menko FH; Maher ER
    J Med Genet; 2010 Jun; 47(6):385-90. PubMed ID: 20522427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.
    Houweling AC; Gijezen LM; Jonker MA; van Doorn MB; Oldenburg RA; van Spaendonck-Zwarts KY; Leter EM; van Os TA; van Grieken NC; Jaspars EH; de Jong MM; Bongers EM; Johannesma PC; Postmus PE; van Moorselaar RJ; van Waesberghe JH; Starink TM; van Steensel MA; Gille JJ; Menko FH
    Br J Cancer; 2011 Dec; 105(12):1912-9. PubMed ID: 22146830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer.
    da Silva NF; Gentle D; Hesson LB; Morton DG; Latif F; Maher ER
    J Med Genet; 2003 Nov; 40(11):820-4. PubMed ID: 14627671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis.
    Akcaglar S; Yavascaoglu I; Vuruskan H; Oktay B
    Int Urol Nephrol; 2008; 40(3):615-20. PubMed ID: 18074239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dubé syndrome not linked to the FLCN locus.
    Starink TM; Houweling AC; van Doorn MB; Leter EM; Jaspars EH; van Moorselaar RJ; Postmus PE; Johannesma PC; van Waesberghe JH; Ploeger MH; Kramer MT; Gille JJ; Waisfisz Q; Menko FH
    J Am Acad Dermatol; 2012 Feb; 66(2):259.e1-9. PubMed ID: 21794948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
    Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.